BR112017020975A2 - combinações antelmínticas e seus usos - Google Patents

combinações antelmínticas e seus usos

Info

Publication number
BR112017020975A2
BR112017020975A2 BR112017020975A BR112017020975A BR112017020975A2 BR 112017020975 A2 BR112017020975 A2 BR 112017020975A2 BR 112017020975 A BR112017020975 A BR 112017020975A BR 112017020975 A BR112017020975 A BR 112017020975A BR 112017020975 A2 BR112017020975 A2 BR 112017020975A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
macrocyclic lactone
anthelmintic
combinations
Prior art date
Application number
BR112017020975A
Other languages
English (en)
Inventor
BONDESEN Brenda
Hammerland Lance
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57006415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020975(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Inc filed Critical Merial Inc
Publication of BR112017020975A2 publication Critical patent/BR112017020975A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma composição veterinária compreendendo uma quantidade eficaz de pelo menos um depsipeptido cíclico e pelo menos uma lactona macrocíclica; e um transportador farmaceuticamente aceitável, para o tratamento ou profilaxia de infecção parasitária em um mamífero em que o parasita mostra resistência ao tratamento ou profilaxia com a lactona macrocíclica sozinha.
BR112017020975A 2015-04-02 2016-04-01 combinações antelmínticas e seus usos BR112017020975A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142304P 2015-04-02 2015-04-02
PCT/US2016/025714 WO2016161369A1 (en) 2015-04-02 2016-04-01 Anthelmintic combinations and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112017020975A2 true BR112017020975A2 (pt) 2018-07-10

Family

ID=57006415

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020975A BR112017020975A2 (pt) 2015-04-02 2016-04-01 combinações antelmínticas e seus usos

Country Status (18)

Country Link
US (1) US10993988B2 (pt)
EP (1) EP3277303B1 (pt)
JP (1) JP6899330B2 (pt)
KR (1) KR20170132330A (pt)
CN (1) CN107567334A (pt)
AU (1) AU2016244022A1 (pt)
BR (1) BR112017020975A2 (pt)
CA (1) CA2981489A1 (pt)
CL (1) CL2017002474A1 (pt)
CO (1) CO2017011284A2 (pt)
ES (1) ES2851345T3 (pt)
IL (1) IL254783B (pt)
MX (1) MX2017012510A (pt)
MY (1) MY187835A (pt)
PH (1) PH12017501806A1 (pt)
RU (1) RU2717545C2 (pt)
SG (1) SG11201708008TA (pt)
WO (1) WO2016161369A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167921A (zh) * 2016-11-16 2019-08-23 勃林格殷格翰动物保健美国公司 驱蠕虫缩肽化合物
CA3052054A1 (en) * 2017-02-08 2018-08-16 Boehringer Ingelheim Animal Health USA Inc. In vivo model for parasitic worm infection and methods for evaluating antiparasitic compounds, including compounds active against canine heartworm
KR20200090165A (ko) 2017-11-23 2020-07-28 세바 상뜨 아니말르 기생충 감염 치료용 목시텍틴 함유 조성물
MX2020005573A (es) * 2017-11-29 2020-09-10 Zoetis Services Llc Depsipeptidos endoparasitarios.
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
DE19520275A1 (de) * 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20030129680A1 (en) 2001-10-31 2003-07-10 O'connor Thomas Patrick Multi-analyte assay device
US20070042354A1 (en) 2005-08-19 2007-02-22 Engelhard Eric K Detecting pathogens in companion animals
WO2008102232A1 (en) * 2007-02-21 2008-08-28 Pfizer Limited Benzofuran antiparasitic agents
JP4734656B2 (ja) * 2007-03-30 2011-07-27 国立大学法人群馬大学 Ｐｆ１０２２類の製造法
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2010053517A2 (en) 2008-10-29 2010-05-14 Aroian Raffi V Combination therapy to combat helminth resistance
BE1019407A5 (nl) 2009-11-06 2012-07-03 Momentum Animal Cure Bvba Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels.
EP2531506B1 (en) 2010-02-05 2014-05-14 Intervet International B.V. Spiroindoline compounds for use as anthelminthics
WO2011115840A2 (en) 2010-03-14 2011-09-22 Ibis Biosciences, Inc. Parasite detection via endosymbiont detection
RU2452180C2 (ru) * 2010-08-31 2012-06-10 Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" Комплексная антипаразитарная композиция
AU2010249226C1 (en) 2010-12-08 2017-04-13 Zoetis Services Llc Anthelmintic formulation
AU2010101389C4 (en) 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds

Also Published As

Publication number Publication date
US10993988B2 (en) 2021-05-04
ES2851345T3 (es) 2021-09-06
JP2018510195A (ja) 2018-04-12
KR20170132330A (ko) 2017-12-01
RU2717545C2 (ru) 2020-03-24
IL254783B (en) 2020-11-30
IL254783A0 (en) 2017-12-31
CL2017002474A1 (es) 2018-03-23
SG11201708008TA (en) 2017-10-30
CN107567334A (zh) 2018-01-09
JP6899330B2 (ja) 2021-07-07
AU2016244022A1 (en) 2017-10-26
PH12017501806A1 (en) 2018-04-11
RU2017138118A3 (pt) 2019-07-24
MY187835A (en) 2021-10-26
MX2017012510A (es) 2018-01-30
EP3277303B1 (en) 2020-12-02
US20170020955A1 (en) 2017-01-26
RU2017138118A (ru) 2019-05-06
EP3277303A1 (en) 2018-02-07
CA2981489A1 (en) 2016-10-06
CO2017011284A2 (es) 2018-01-31
WO2016161369A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
BR112017020975A2 (pt) combinações antelmínticas e seus usos
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112015030389A2 (pt) uso de i) uma fonte de proteína, ii) um prebiótico e iii) um probiótico para a fabricação de uma composição nutricional para o tratamento ou a prevenção de infecção em um indivíduo alérgico
BR112017011440A2 (pt) uma composição antimicrobiana
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112016002233A2 (pt) composições de adoçante
CO7350655A2 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112017006113A2 (pt) combinações sinérgicas de auristatina
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
NI201500118A (es) Imidazopiridazinas sustituidas
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
BR112017020796A2 (pt) compostos, composição farmacêutica e kit
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2716 DE 24-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.